

# WHO Drug Information

---

## Contents

<b>Quality Assurance Issues</b>			
Good pharmaceutical trade and distribution practices	1	Levacetylmethadol: labelling changes	19
<b>Personal Perspectives</b>		Isotretinoin and depression	19
Risk assessment as an element of drug control	6	New glucose test for adult diabetics	19
<b>Current Topics</b>		Anti-inflammatory analgesics: hepatic reactions	20
The WHO Model List of Essential Drugs: latest developments	12	Gentamicin ear drops: toxicity	20
Sequencing of the <i>Anopheles gambiae</i> genome	14	Tetracycline and benign intracranial hypertension	20
Multilateral initiative on Malaria: benefits to the global community	15	Ergotamine and erythromycin interaction	21
China revises its pharmaceutical law	16	Celecoxib and warfarin interaction	21
<b>Regulatory and Safety Matters</b>		Cerivastatin: rare effect of rhabdomyolysis	22
New formulation of DTP vaccine	17	SSRIs and increased ocular pressure	22
Bupropion safety reminder	17	Amfepramone: new cases of primary pulmonary hypertension	23
Propofol: reactions to long-term high doses	17	Bufexamac and contact eczema	23
Propofol: not for paediatric use	18	Droperidol: prolongation of the QT interval	23
Leflunomide: hepatic reactions	18	Mofezolac: revised data sheet	24
Rapacuronium bromide voluntarily withdrawn	18	Monoethanolamine oleate: revised data sheet	24
Levacetylmethadol withdrawn	19	Rivastigmine: revised product information	24
		Sarpogrelate: revised data sheet	25
		<b>ATC/DDD Classification</b>	
		ATC/DDD methodology: a country perspective	26
		<b>Recommended International Nonproprietary Names: List 45</b>	31